Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 47, 2012 - Issue 6
Submit an article Journal homepage
565
Views
15
CrossRef citations to date
0
Altmetric
Inflammatory Bowel Disease

Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn's disease

Åse RiisDepartment of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
,
Tom C. MartinsenDepartment of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway;Department of Gastroenterology and Hepatology, St. Olavs Hospital, Trondheim, Norway
,
Helge L. WaldumDepartment of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway;Department of Gastroenterology and Hepatology, St. Olavs Hospital, Trondheim, Norway
&
Reidar FossmarkDepartment of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway;Department of Gastroenterology and Hepatology, St. Olavs Hospital, Trondheim, NorwayCorrespondence[email protected]
Pages 649-657 | Received 10 Jan 2012, Accepted 27 Feb 2012, Published online: 04 Apr 2012

Citations (15)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Samuele Naviglio, Paolo Giuffrida, Gabriele Stocco, Marco Vincenzo Lenti, Alessandro Ventura, Gino Roberto Corazza & Antonio Di Sabatino. (2018) How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 12:8, pages 797-810.
Read now
Thomas R. Einarson, Basil G. Bereza, Xin Ying Lee & Filippo Lelli. (2017) Dose escalation of biologics in Crohn’s disease: critical review of observational studies. Current Medical Research and Opinion 33:8, pages 1433-1449.
Read now
Konstantinos Papamichael, Gerassimos J. Mantzaris & Laurent Peyrin-Biroulet. (2016) A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn’s disease. Expert Opinion on Drug Safety 15:4, pages 493-501.
Read now

Articles from other publishers (12)

Jiri Bronsky, Ivana CopovaDenis KazekaTereza LerchovaKatarina MitrovaKristyna PospisilovaMiroslava SulovcovaKristyna ZarubovaOndrej Hradsky. (2022) Adalimumab vs Infliximab in Pediatric Patients With Crohn's Disease: A Propensity Score Analysis and Predictors of Treatment Escalation. Clinical and Translational Gastroenterology 13:5, pages e00490.
Crossref
Boran Yu, Libo Zhao, Siyao Jin, Huan He, Jing Zhang & Xiaoling Wang. (2022) Model-Based Meta-Analysis on the Efficacy of Biologics and Small Targeted Molecules for Crohn’s Disease. Frontiers in Immunology 13.
Crossref
Laura Guberna, Olga P. Nyssen, María Chaparro & Javier P. Gisbert. (2021) Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis. Journal of Clinical Medicine 10:10, pages 2132.
Crossref
Vito Annese, Rahul Nathwani, Maryam Alkhatry, Ahmad Al-Rifai, Sameer Al Awadhi, Filippos Georgopoulos, Ahmad N. Jazzar, Ahmed M. Khassouan, Zaher Koutoubi, Mazen S. Taha & Jimmy K. Limdi. (2021) Optimizing biologic therapy in inflammatory bowel disease: a Delphi consensus in the United Arab Emirates. Therapeutic Advances in Gastroenterology 14, pages 175628482110653.
Crossref
Farzad Alinaghi, Hasan Göcker Tekin, Johan Burisch, Jashin J Wu, Jacob P Thyssen & Alexander Egeberg. (2020) Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis 14:3, pages 351-360.
Crossref
Yoshifumi Watanabe, Norikatsu Miyoshi, Shiki Fujino, Hidekazu Takahashi, Naotsugu Haraguchi, Taishi Hata, Chu Matsuda, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori & Tsunekazu Mizushima. (2019) Cumulative Inflammation Could Be a Risk Factor for Intestinal Failure in Crohn’s Disease. Digestive Diseases and Sciences 64:8, pages 2280-2285.
Crossref
Lone Larsen, Asbjørn Mohr Drewes, Marie Christine Hede Broberg, Jan Fallingborg, Bent Ascanius Jacobsen, Thomas Bo Jensen & Tine Jess. (2018) Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999–2014. Inflammatory Bowel Diseases 24:2, pages 433-439.
Crossref
Pablo Olivera, Linda Thiriet, Amandine Luc, Cedric Baumann, Silvio Danese & Laurent Peyrin-Biroulet. (2017) Treatment Persistence for Infliximab Versus Adalimumab in Crohnʼs Disease. Inflammatory Bowel Diseases 23:6, pages 976-985.
Crossref
Berkeley N. Limketkai, Alyssa M. Parian, Neha D. Shah & Jean-Frédéric Colombel. (2016) Short Bowel Syndrome and Intestinal Failure in Crohnʼs Disease. Inflammatory Bowel Diseases 22:5, pages 1209-1218.
Crossref
Michael D. Mandel, Anita Balint, Petra A. Golovics, Zsuzsanna Vegh, Anna Mohas, Blanka Szilagyi, Agnes Szabo, Zsuzsanna Kurti, Lajos S. Kiss, Barbara D. Lovasz, Krisztina B. Gecse, Klaudia Farkas, Tamas Molnar & Peter L. Lakatos. (2014) Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres. Digestive and Liver Disease 46:11, pages 985-990.
Crossref
João Costa, Fernando Magro, Daniel Caldeira, Joana Alarcão, Rita Sousa & António Vaz-Carneiro. (2013) Infliximab Reduces Hospitalizations and Surgery Interventions in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases 19:10, pages 2098-2110.
Crossref
Richard B Gearry, Michael A Kamm, Ailsa L Hart, Paul Bassett, Simon M Gabe & Jeremy M Nightingale. (2013) Predictors for developing intestinal failure in patients with Crohn's disease. Journal of Gastroenterology and Hepatology 28:5, pages 801-807.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.